Drug Profile


Alternative Names: Bifril; MEN 8029; SQ 26991; Zantipress; Zofenil; Zofenopril calcium; Zopranol

Latest Information Update: 17 May 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Menarini
  • Class Antihypertensives; Imino acids
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Hypertension; Myocardial infarction
  • Discontinued Heart failure

Most Recent Events

  • 21 Dec 2001 Discontinued-II for Heart failure in European Union (PO)
  • 12 Dec 2001 Launched for Hypertension in Netherlands (PO)
  • 12 Dec 2001 Launched for Myocardial infarction in Netherlands (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top